Global Hepatocellular Carcinoma Drugs Market 2017-2021

肝細胞癌治療薬の世界市場2017-2021:化学療法、小線源療法、アブレーション

◆タイトル:Global Hepatocellular Carcinoma Drugs Market 2017-2021
◆商品コード:IRTNTR14735
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年9月8日
◆ページ数:86
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:Healthcare and Life Sciences
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社が発行した当調査レポートでは、肝細胞癌治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、肝細胞癌治療薬の世界市場規模及び予測、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。Technavio社は肝細胞癌治療薬の世界市場が2017-2021年期間中に年平均3.40%成長すると予測しています。当レポート上に記載されている主な企業はBayer、Eli Lilly、Johnson and Johnson、Pfizer等です。

About Hepatocellular Carcinoma Drugs
HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.

Technavio’s analysts forecast the global hepatocellular carcinoma drugs market to grow at a CAGR of 3.40% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global hepatocellular carcinoma drugs market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs in HCC treatment market.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Hepatocellular Carcinoma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Bayer
• Eli Lilly
• Johnson and Johnson
• Pfizer

[Other prominent vendors]
• Bristol-Myers Squibb
• Celgene
• F. Hoffmann-la Roche
• Gilead
• GlaxoSmithKline
• Merck
• Novartis
• Salix Pharmaceuticals
• Transgene

[Market driver]
• Growing cases of hepatitis B and C infections
• For a full, detailed list, view our report

[Market challenge]
• Stringent government regulations and trial failure in the late stage of drug development
• For a full, detailed list, view our report

[Market trend]
• Increase in R&D activities for liver cirrhosis medication
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market landscape
• Market size and forecast
• Five forces analysis

PART 06: Pipeline landscape

PART 07: Market segmentation by therapy
• Chemotherapy
• Brachytherapy
• Ablation therapy

PART 08: Geographical segmentation
• HCC drugs market in Americas
• HCC drugs market in EMEA
• HCC drugs market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges
• Market drivers
• Market challenges

PART 11: Market trends
• Increase in R&D activities for liver cirrhosis medication
• Rise in awareness

PART 12: Vendor landscape
• Competitive scenario

PART 13: Key vendor analysis
• Bayer
• Eli Lilly
• Johnson and Johnson
• Pfizer
• Other prominent vendors

PART 14: Appendix
• List of abbreviations

[List of Exhibits] 
Exhibit 01: Functions of liver
Exhibit 02: Causes of HCC
Exhibit 03: Global HCC drugs market
Exhibit 04: Global HCC drugs market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis of global HCC drugs market
Exhibit 06: Five forces analysis
Exhibit 07: Pipeline based on vendors
Exhibit 08: Key clinical trials
Exhibit 09: Global HCC drugs market segmentation based on therapies
Exhibit 10: Global HCC drugs market share as per therapies 2016 and 2021
Exhibit 11: Major types of chemotherapy
Exhibit 12: Global HCC chemotherapy drugs market 2016-2021 ($ millions)
Exhibit 13: NEXAVAR: Drug overview
Exhibit 14: STIVARGA: Drug overview
Exhibit 15: Global HCC brachytherapy drugs market 2016-2021 ($ millions)
Exhibit 16: Global HCC ablation therapy market 2016-2021 ($ millions)
Exhibit 17: Global HCC drugs market share by geography 2016 and 2021
Exhibit 18: Global HCC drugs market revenues by geography 2016-2021 ($ millions)
Exhibit 19: Market scenario in Americas
Exhibit 20: HCC drugs market in Americas 2016-2021 ($ millions)
Exhibit 21: Liver cancer scenario in the US 2016
Exhibit 22: Market scenario in EMEA
Exhibit 23: HCC drugs market in EMEA 2016-2021 ($ millions)
Exhibit 24: Top five countries with highest incidence of liver cancer
Exhibit 25: Market scenario in APAC
Exhibit 26: HCC drugs market in APAC 2016-2021 ($ millions)
Exhibit 27: Proportions of HBV and HCV-related HCC in APAC
Exhibit 28: Hepatitis C scenario 2016
Exhibit 29: Hepatitis B scenario 2016
Exhibit 30: Lifestyle disease effect on liver
Exhibit 31: Global liver transplants scenario 2014
Exhibit 32: Percentage distribution of transplants by organ in the US 1988-2016
Exhibit 33: Effects of chemotherapy drugs on human body
Exhibit 34: Competitive structure analysis of global HCC drugs market 2016
Exhibit 35: Strategic success factors of companies in global HCC drugs market
Exhibit 36: Bayer: Key highlights
Exhibit 37: Bayer: Strength assessment
Exhibit 38: Bayer: Strategy assessment
Exhibit 39: Bayer: Opportunity assessment
Exhibit 40: Eli Lilly: Key highlights
Exhibit 41: Eli Lilly: Strength assessment
Exhibit 42: Eli Lilly: Strategy assessment
Exhibit 43: Eli Lilly: Opportunity assessment
Exhibit 44: Johnson & Johnson: Key highlights
Exhibit 45: Johnson & Johnson: Strength assessment
Exhibit 46: Johnson & Johnson: Strategy assessment
Exhibit 47: Johnson & Johnson: Opportunity assessment
Exhibit 48: Pfizer: Key highlights
Exhibit 49: Pfizer: Strength assessment
Exhibit 50: Pfizer: Strategy assessment
Exhibit 51: Pfizer: Opportunity assessment



【掲載企業】

Bayer, Eli Lilly, Johnson and Johnson, Pfizer, Bristol-Myers Squibb, Celgene, F. Hoffmann-la Roche, Gilead, GlaxoSmithKline, Merck, Novartis, Salix Pharmaceuticals, and Transgene.


★調査レポート[肝細胞癌治療薬の世界市場2017-2021:化学療法、小線源療法、アブレーション] (Global Hepatocellular Carcinoma Drugs Market 2017-2021 / IRTNTR14735)販売に関する免責事項
[肝細胞癌治療薬の世界市場2017-2021:化学療法、小線源療法、アブレーション] (Global Hepatocellular Carcinoma Drugs Market 2017-2021 / IRTNTR14735)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆